

04 NOVEMBER 2003 04.11.03  
01 CA 03 / U 1 3 9 0

PA 1067535

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

September 25, 2003

REC'D 19 DEC 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/410,502

FILING DATE: September 12, 2002

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) or (b)



By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS

*N. Williams*  
N. WILLIAMS

Certifying Officer

BEST AVAILABLE COPY

09/12/02  
13800 U.S. PTO

09-16-02

60410507 120177 APHC

Approved for use through 10/31/2002. OMB 0851-0032  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


# PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

EL556128797US

13800 U.S. PTO  
60410507

INVENTOR(S)					
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)			
Stephen G. Michael	Withers Jahn	Vancouver, CANADA Vancouver, CANADA			
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
Engineered Enzymes and Their Use for Synthesis of Thioglycosides					
Direct all correspondence to. CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number		021121		 021121	
OR		Type Customer Number here			
<input type="checkbox"/> Firm or Individual Name		PATENT TRADEMARK OFFICE			
Address					
Address					
City	State	ZIP			
Country	Telephone	Fax			
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification	Number of Pages	17	<input type="checkbox"/> CD(s), Number		
<input checked="" type="checkbox"/> Drawing(s)	Number of Sheets	2	<input type="checkbox"/> Other (specify)		
<input type="checkbox"/> Application Data Sheet See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/>	Applicant claims small entity status. See 37 CFR 1.27			FILING FEE AMOUNT (\$)	
<input type="checkbox"/>	A check or money order is enclosed to cover the filing fees				
<input checked="" type="checkbox"/>	The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number.			15-0610	
<input checked="" type="checkbox"/>	Payment by credit card. Form PTO-2038 is attached			\$80.00	
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are _____					

Respectfully submitted,

SIGNATURE

*Marina T. Larson*

TYPED or PRINTED NAME

Marina T. Larson, Ph.D.

TELEPHONE

970-468-6600

Date

09/12/2002

REGISTRATION NO.  
(if appropriate)  
Docket Number.

32,038

UBC.P-034PV

## USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

BEST AVAILABLE COPY

## Engineered Enzymes and Their Use for Synthesis of Thioglycosides

Background of the Invention

This application relates to engineered enzymes, and to their use for the synthesis of thioglycosides.

Carbohydrate mimetics that are resistant towards enzymatic hydrolysis have proven to be useful as competitive glycosidase inhibitors and therefore have potential as therapeutics. Thioglycosides, in which the glycosidic oxygen has been replaced by sulfur, have been especially valuable as stable glycoside analogues in a range of studies of glycosidases, both as competitive inhibitors, e.g. for  $\alpha$ -L-fucosidases,<sup>[1]</sup> pancreatic  $\alpha$ -amylase<sup>[2]</sup> or for cellulases,<sup>[3]</sup> and recently in the formation of stable complexes for X-ray crystallography analysis, e.g. with endoglucanase Cel7B from *Fusarium oxysporum*,<sup>[4]</sup> maize  $\beta$ -glucosidase ZMGlu1,<sup>[5]</sup> barley  $\beta$ -D-glucan glucohydrolase,<sup>[6]</sup> endoglucanase Cel5A<sup>[7]</sup> or *E. coli* maltodextrin phosphorylase (MalP),<sup>[8]</sup> and they are gaining increasing interest as targets for the pharmaceutical industry.<sup>[9]</sup>

The chemical synthesis of thioglycosides has been achieved via glycosylation of thioacceptors with activated glycosyl donors,<sup>[10], [11], [12]</sup> via the S<sub>N</sub>2 reaction of 1-thio sugars with activated acceptors<sup>[13]</sup> and via Michael addition of 1-thiosugars to  $\alpha,\beta$ -unsaturated systems;<sup>[14]</sup> all routes involve numerous protection and deprotection steps and require good control of anomeric stereochemistry.

The few naturally occurring thioglycosides belong to the family of glucosinolates and are found in cruciferous plants.<sup>[15]</sup> The enzymes that catalyze the formation of the thioglycosidic linkages, S-glucosyltransferases, have been purified from plant extracts,<sup>[16]</sup> as well as cloned into and expressed from *E. coli*.<sup>[17]</sup> However, no useful enzymatic syntheses of thioglycosidic linkages *in vitro* have been reported - such approaches would be valuable.

The action of retaining glycosidases on glycosides is in most instances mediated by two key active site amino acid residues, the catalytic nucleophile and the catalytic acid/base. We have previously reported on the efficient synthesis of O-glycosidic linkages in oligosaccharides by the use of retaining glycosidases that lack the catalytic

## Provisional Patent Application

nucleophile (glycosynthases), in conjunction with activated donors of the opposite anomeric configuration of the natural substrate.<sup>[18], [19], [20]</sup>

In order to facilitate the synthesis of thioglycosides of diverse structure, it would be useful to have an enzymatic methodology. It is an object of the present invention to provide such methods for making thioglycosides.

Summary of the Invention

It has now been surprisingly found that mutant glycosidases in which the amino acid in the active site that serves as the acid base-catalyst is converted from a carboxylic acid to some other amino acid (for example to a simple alkyl, as in alanine or glycine) (thioglycoligases) can catalyze the reaction of a thiosugar acceptor and an activated donor to form a thioglycoside. Thioglycoligases represent a novel class of mutant enzymes, and represent a first aspect of the invention. Thioglycoligases can be used in accordance with the method of the invention to couple a thiosugar acceptor and an activated donor to form a thioglycoside. By selection of the donor and acceptor species, as well as the specific enzyme employed, thioglycosides of different structure and stereochemistry can be obtained.

Brief Description of the Drawings

Fig. 1 shows the hydrolysis of a disaccharide within the active site of a normal glycosidase enzyme which retains stereochemical configuration during hydrolysis;

Fig. 2 shows the hydrolysis of a disaccharide within the active site of a normal glycosidase enzyme which inverts stereochemical configuration during hydrolysis; and




Fig. 3 shows HPLC chromatograms of the Man2A E429A catalyzed reaction of the two competing acceptors pNP-Xyl (5.5 mM) and its thio analogue 6 (5.5 mM) with varying concentrations of DNP-Man: a) 3.75 mM, b) 22 mM. Arrows indicate the elution of the O-linked disaccharides, 10 is the S-linked disaccharide. Experimental details are provided in the Supporting Information.

#### Detailed Description of the Invention

In present invention provides a novel method for the synthesis of S-glycosidic linkages in oligosaccharides by use of glycosidases that lack the catalytic acid/base amino acid residue as a result of a mutation. Glycosidase enzymes can be classified as being either "retainers" because they retain the stereochemistry of the bond being broken during hydrolysis, or "inverters" because they invert the stereochemistry of the bond being broken during hydrolysis. The mutant enzymes of the present invention, may be referred to as thioglycoligases, can be formed by mutation of retaining or inverting, alpha or beta glycosidases.

Normal stereochemistry retaining glycosidase enzymes have two carboxylic acid groups in the active site of the enzyme as shown generally in Fig. 1. One of these groups functions as an acid/base catalyst (labeled as group 1 in Fig 1) and the other as a nucleophile (group 2 in Fig. 1). The nucleophile group 2 forms a glycosyl-enzyme intermediate which is then cleaved by the acid/base catalyst group 1 to result in a hydrolyzed glycoside in which the stereochemistry has been maintained.

## Provisional Patent Application

Normal stereochemistry inverting enzymes also have two carboxylic acid groups in the active site of the enzyme as shown generally in Fig. 2. In inverting enzymes, however, one of these groups functions as an acid catalyst (labeled as group 3 in Fig 2) and the other as a base catalyst (group 4 in Fig. 2). The acid catalyst group 3 protonates the hemiacetal-hydroxyl group of the glycosyl donor molecule, making it a good leaving group, at the same time that the base catalyst group 4 deprotonates a donor molecule (water or HOR) allowing it to replace the leaving hydroxyl group with inversion of stereochemistry.

The present invention provides mutant forms of both retaining and inverting enzymes in which one of the two carboxylic acid amino acids in the active site has been replaced with a different amino acid. Such mutations provide enzymes which are effective to catalyze the formation of thioglycosides.

Enzymes to which the methodology of the present invention may be employed include, for example,  $\beta$ -glucosidases,  $\beta$ -galactosidases,  $\beta$ -mannosidases,  $\beta$ -N-acetyl glucosaminidases,  $\beta$ -N-acetyl galactosaminidases,  $\beta$ -xylosidases,  $\beta$ -fucosidases, cellulases, xylanases, galactanases, mannanases, hemicellulases, amylases, glucoamylases,  $\alpha$ -glucosidases,  $\alpha$ -galactosidases,  $\alpha$ -mannosidases,  $\alpha$ -N-acetyl glucosaminidases,  $\alpha$ -N-acetyl galactosaminidases,  $\alpha$ -xylosidases,  $\alpha$ -fucosidases, neuraminidases/sialidases such as those from: *Agrobacterium sp.*, *Bacillus sp.*, *Caldocellum sp.*, *Clostridium sp.*, *Escherichia coli*, *Kluveromyces sp.*, *Klebsiella sp.*, *Lactobacillus sp.*, *Aspergillus sp.*, *Staphylococcus sp.*, *Lactobacillus sp.*, *Butyrovibrio sp.*, *Ruminococcus sp.*, *Sulfolobus sp.*, *Schizophyllum sp.*, *Trichoderma sp.*, *Cellulomonas sp.*, *Erwinia sp.*, *Humicola sp.*, *Pseudomonas sp.*, *Thermoascus sp.*, *Phaseolus sp.*, *Persea sp.*, *Fibrobacter sp.*, *Phanaerochaete sp.*, *Microbispora sp.*, *Saccharomyces sp.*, *Hordeum vulgare*, *Glycine max*, *Saccharomycopsis sp.*, *Rhizopus sp.*, *Nicotiana*, *Phaseolus sp.*, rat, mouse, rabbit, cow, pig, and human sources. Preferred enzymes in accordance with the invention are mutant forms of retaining glycosidase enzymes.

In the enzymes of the present invention, one of the two amino acid residues with the active carboxylic acid side chains is changed to a different amino acid which does not act as an acid/base catalyst (in the case of a retaining enzyme) or as an acid catalyst (in the case of an inverting enzyme). Thus, in general, the substitution will involve replacing

## Provisional Patent Application


the glutamic acid or aspartic acid residue of the wild-type enzyme with alanine, glycine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, asparagine, glutamine, histidine, proline, phenylalanine, or tyrosine. Preferably, the substituted amino acid will have a side chain of approximately equal or smaller size to the side chain of the wild-type amino acid residue to avoid significant changes to the size and shape of the active site.

Glycosidases of use in the invention are based upon wild-type enzymes which can be categorized as either alpha or beta glycosidases based upon the anomeric configuration of the natural substrate. When the enzyme modified to form the thioglycoligase used is a retaining enzyme, the resulting thioglycoligase should be used with a donor and acceptor having the same anomeric configuration as each other (for example alpha acceptor with alpha donor) and the same anomeric configuration as the natural substrate. When the enzyme modified to form the thioglycoligase used is a retaining enzyme, the resulting thioglycoligase should be used with an acceptor having the same configuration as the natural substrate and with a donor of opposite configuration.

In accordance with the method of the invention, thioglycosides of the general structure A-S-B, where A and B are both sugar moieties and are formed by the enzymatic coupling of A-X and HS-B using a mutant glycosidase enzyme, wherein X is an appropriate leaving group. In addition to consideration of stereochemistry based on the enzyme being employed, the donors and acceptors are selected based on the desired product, i.e., a glucoside where a glucoside is a desired component, a mannoside where a mannose is a desired component, etc. The specific donor and acceptor are also suitably chosen in light of the double displacement mechanism of retaining glycosidases first proposed by Koshland<sup>[21]</sup> (Scheme 1): In the glycosylation step the concerted action of the catalytic acid/base (protonated, acting as an acid) and the catalytic nucleophile (deprotonated) leads to the departure of the aglycon group and to the formation of the covalent glycosyl-enzyme intermediate (A). Use of a mutant glycosidase in which the catalytic acid/base residue has been replaced by a non catalytically active residue necessitates glycosyl donors with good leaving groups that do not need acid catalysis, e.g. dinitrophenyl groups, to allow formation of the glycosyl-enzyme intermediate (B). However, turnover of that intermediate via transglycosylation to an oxygen acceptor is impractically slow, since general base catalysis is required to speed this step (A). The

## Provisional Patent Application

acid/base mutant therefore requires strong nucleophiles as acceptors that do not need general base catalysis (B). As a practical consequence, the method of the present invention makes use of a thiosugar acceptor with a free thiol, for example, a para-nitrophenyl 4-deoxy-4-thio glycoside or 3'-deoxy-3'-thio lactose. The thiosugar may be a monosaccharide, an oligosaccharide, or a polysaccharide, and may itself contain thioglycoside linkages as a result of repeated cycles of the method of the invention. The donor species is one having a good leaving group. Typically, such a "good leaving group" will have a leaving group ability from an acetal center equal to or greater than that of p-nitrophenol.



Scheme 1. Mechanism of a retaining glycosidase: Glycosylation and deglycosylation with wild type A) and acid/base mutant B). DNP = dinitrophenyl, Nu = nucleophile.

Earlier experiments revealed that small anionic molecules, such as  $\text{N}_3^-$ ,  $\text{AcO}^-$ ,  $\text{HCO}_2^-$ <sup>[22]</sup> and  $\text{F}^-$ <sup>[23]</sup> rescue the reaction by enhancing the rate of the deglycosylation step.



## Provisional Patent Application


In the present study we exploit this concept to allow the synthesis of thiooligosaccharides by use of deoxythio sugars as nucleophilic acceptors that do not need base catalysis in the deglycosylation step. In summary, our approach requires activated donor glycosides, such as dinitrophenyl glycosides, and chemically synthesized deoxythio sugars as acceptors in conjunction with mutant glycosidases modified at the acid/base position.

We have probed our strategy using the alanine acid/base mutants of two retaining  $\beta$ -glycosidases, the  $\beta$ -glucosidase from *Agrobacterium* sp. Abg E171A and the  $\beta$ -mannosidase from *Cellulomonas fimi* Man2A E429A. The mutant Abg E171A was generated by site-directed mutagenesis by a 'megaprimer' PCR method using three oligonucleotide primers, one containing the mutation.<sup>[19]</sup> The purified product of the first PCR reaction served as a megaprimer in the second PCR reaction. The purified gene was subcloned into an expression vector, and after expression the protein was purified in a single step by  $\text{Ni}^{2+}$ -chelation chromatography. The mutant Man2A E429A was the same protein sample described by Zechel et al.<sup>[23]</sup>

As donors we chose the readily available dinitrophenyl glycosides 2,4-dinitrophenyl  $\beta$ -D-glucopyranoside (DNP-Glc) for studies with the mutant glucosidase and 2,5-dinitrophenyl  $\beta$ -D-mannopyranoside (DNP-Man) for experiments involving the mutant mannosidase.<sup>[23]</sup> The low  $\text{pK}_a$  values of 3.96 for 2,4-dinitrophenol and 5.15 for 2,5-dinitrophenol render acid catalysis for the glycosylation step unnecessary. As an acceptor we initially chose para-nitrophenyl 4-deoxy-4-thio- $\beta$ -D-glucopyranoside (3) since the parent sugar para-nitrophenyl  $\beta$ -D-glucopyranoside (PNP-Glc) acts as an excellent acceptor for both wild type and nucleophile mutant forms of Abg<sup>[18]</sup> and Man2A<sup>[20]</sup> undergoing transfer preferentially to the 4-hydroxyl. The chemical synthesis of the deoxythio sugar 3 was readily achieved via regioselective protection of the *galacto* sugar, activation of the unprotected axial alcohol by formation of the triflate, nucleophilic substitution with thioacetate with inversion of configuration and finally Zemplen deprotection while excluding oxygen (in the presence of DTT). Anaerobic conditions, even during the enzymatic reactions, are compulsory to prevent oxidation of the thiols to disulfides.


Upon incubation of 3 (20 mM) with the appropriate donor (45 mM) and mutant enzyme (~1 mg/ml) in phosphate buffered solutions at pH 6.8 TLC analysis revealed that

a new product with the expected mobility of a disaccharide was formed quite rapidly in each case. These products were stable towards hydrolysis by both the wild type and mutant enzymes. By contrast, incubation of the wild type enzymes with the appropriate DNP sugar donors and thiosugar acceptor **3** resulted in no significant formation of disaccharide. A novel enzymatic coupling reaction was therefore occurring involving specific thiolinkage formation. This was confirmed by isolation of the products of the enzymatic reactions via silica gel chromatography after acetylation.  $^1\text{H}$  and  $^{13}\text{C}$  NMR analysis as well as mass spectrometry revealed that the products formed were indeed sulfur linked disaccharides (Scheme 2).



Scheme 2. Enzymatic synthesis of thioglycosides **7** and **9**. Experimental details and spectroscopic data are provided in the Supporting Information. DNP = dinitrophenyl, pNP = para-nitrophenyl.

These extremely encouraging results led us to question whether the regiochemical outcome of the transglycosylation reaction could be controlled by virtue of the location of the thiol within the acceptor sugar. We therefore synthesized and tested para-nitrophenyl 4-deoxy-4-thio- $\beta$ -D-xylopyranoside (**6**) as an acceptor for the two enzymes. Previous studies with both the wild type Abg and its nucleophile mutant had revealed that para-nitrophenyl  $\beta$ -D-xylopyranoside (PNP-Xyl) is an excellent acceptor substrate, but that transfer, surprisingly, occurred exclusively to the 3-position.<sup>[18]</sup> Use of **6** as an acceptor would reveal whether the greater nucleophilicity of the thiol controls the reaction outcome. Indeed, incubation of **6** with Abg E171A and DNP-Glc resulted in an excellent yield (79%) of the sulfur-linked disaccharide, as revealed by  $^1\text{H}$  and  $^{13}\text{C}$  NMR analysis as well as ESI-MS. Similarly, incubation of **6** with Man2A E429A and DNP-Man produced, in 82% yield, the  $\beta$ (1-4) linked thiodisaccharide product (Scheme 3).



Scheme 3. Enzymatic synthesis of thioglycosides 8 and 10. Experimental details and spectroscopic data are provided in the Supporting Information. DNP = dinitrophenyl, pNP = para-nitrophenyl.

Interestingly, control reactions in which the parent sugars para-nitrophenyl  $\beta$ -D-xylopyranoside (pNP-Xyl) and para-nitrophenyl  $\beta$ -D-glucopyranoside (pNP-Glc) were used as acceptors for Man2A E429A in the presence of DNP-Man, showed the formation of disaccharide products, but only very slowly (However, no formation of disaccharides was observed when using pNP-Glc or pNP-Xyl with Abg E171A in the presence of DNP-Glc as donor). In order to assess the relative rates of transfer to the oxygen and sulfur nucleophiles in the case of Man 2A E429A we established a competition reaction in which equimolar amounts of pNP-Xyl and its 4-thio analogue 6 were incubated together with DNP-Man as donor and Man2A E429A (Figure 3). When the concentration of donor was limiting (one third of the concentration of acceptors) we saw exclusive formation of the S-linked disaccharide 10 (a). However, upon addition of further donor to a final concentration twice that of the acceptors the O-linked disaccharides (indicated by arrows) were formed (b). Integration of HPLC peaks indicates that transfer to the thiosugar acceptor is at least 100-fold faster than transfer to its oxygen analogue. These results were confirmed by ESI-MS analysis.

The glycosynthases have proven to be powerful tools for the synthesis of O-linked oligosaccharides. In the present invention, the utility of the glycosynthase enzymes is extended and shown to have the further property of being able to produce designed thioglycosides in significant yields. Furthermore, the methodology is general, as demonstrated with two different enzymes from two separate glycosidase families, and will prove to be of considerable value in the specific assembly of thiooligosaccharides for mechanistic and possibly therapeutic use.

UBC.P-034-PV

## Provisional Patent Application

A further application of the method of the present invention is the formation of thioglycosidic linkages within proteins in order to generate thioglycosidic analogues of therapeutic glycoproteins, which would be stable to glycosidase-catalysed degradation in vivo. Many therapeutic proteins, such as Epo, TPA, Enbrel, Ceredase, are glycosylated proteins...and the glycosylation is important to their function. Typically these proteins have an oligosaccharide on their surface which terminates in a sialyl galactose structure. If all the sialic acids are present the protein has a long circulatory half-life (desirable). However, if any of the sialic acids are missing and the galactose is exposed the protein gets "taken up" by receptors in the liver and cleared from the circulation. Therefore production of glycoproteins that do not lose their sialic acids is desirable because such proteins would have much longer circulatory half-lives. Thioglycosidic modification would provide this benefit. However, at present it is not possible to chemically assemble thioglycosidic bonds right on the protein surface using conventional approaches, as the reagents are too harsh, and no natural enzymes are available to do this job. Mutant thioglycoligase enzymes, however, are perfect for the task.

Supporting Information concerning experimentsGeneral:

$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded on Bruker Avance-300 or Avance-400 Spectrometers. Chemical shifts are reported in  $\delta$  units (ppm) using residual  $^1\text{H}$  and  $^{13}\text{C}$  signals of the deuterated solvents as reference:  $\delta_{\text{H}}$  ( $\text{CDCl}_3$ ) 7.26,  $\delta_{\text{H}}$  ( $\text{CD}_3\text{OD}$ ) 3.31,  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ) 77.0,  $\delta_{\text{C}}$  ( $\text{CD}_3\text{OD}$ ) 49.0. Electrospray mass spectra were recorded on a PE Sciex API 300 LC/MS/MS instrument by direct injection of the compounds in a 1:1  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  solution. Melting points were determined with a Mel-Temp II apparatus and are not corrected. Silica gel 60 (230-400 mesh) from SiliCycle was used for column chromatography. The petroleum ether used for column chromatography had a boiling point range from 35-60°C. Amberlite IR-120PLUS from Aldrich was transformed into the  $\text{H}^+$ -form before use. All reagents and solvents were purchased from Aldrich, Fluka, Sigma or Fisher Scientific. Solvents were dried over  $\text{CaH}_2$  ( $\text{CH}_2\text{Cl}_2$ , pyridine, toluene,

acetonitrile), over Mg (methanol) or over molecular sieves 4Å (DMF). All reactions were carried out under a dry nitrogen atmosphere.

Chemical Synthesis of deoxythio sugar acceptors:

*p*-Nitrophenyl 2,3,6-tri-*O*-benzoyl- $\beta$ -D-galactopyranoside (1):

Benzoyl chloride (1.50 ml, 1.82 g, 12.9 mmol) was added dropwise to a solution of *p*-nitrophenyl  $\beta$ -D-galactopyranoside (1.00 g, 3.32 mmol) in DMF (15 ml) and pyridine (15 ml) at -20°C. After stirring for 5 h at -5°C another 0.30 ml of benzoyl chloride (0.36 g, 2.59 mmol) was added dropwise, and the solution was stirred for 2 h at -5°C. Water (10 ml) was added and the mixture was concentrated by evaporation in vacuo. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub>, and the organic phase was washed sequentially with saturated aqueous NaHCO<sub>3</sub>, 1 M HCl and brine, dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo. Column chromatography (toluene → 4:1 toluene/EtOAc) followed by crystallization from hot toluene yielded 1 (850 mg, 1.39 mmol, 42%); mp 180-181°C; <sup>1</sup>H-NMR (400 MHz):  $\delta_H$  (CDCl<sub>3</sub>): 8.05 (m, 2 H, Ar), 8.0 - 7.3 (m, 15 H, 3xBz), 7.06 (m, 2 H, Ar), 6.10 (dd, 1 H,  $J_{2,3}$  10.3 Hz,  $J_{2,1}$  7.9 Hz, H-2), 5.48 (dd, 1 H,  $J_{3,2}$  10.3 Hz,  $J_{3,4}$  3.2 Hz, H-3), 5.40 (d, 1 H,  $J_{1,2}$  7.9 Hz, H-1), 4.76 (dd, 1 H,  $J_{6,6}$  11.7 Hz,  $J_{6,5}$  5.1 Hz, H-6), 4.68 (dd, 1 H,  $J_{6,6}$  11.7 Hz,  $J_{6,5}$  7.7 Hz, H-6), 4.47 (m, 1 H, H-4), 4.31 (m, 1 H, H-5), 2.66 (d, 1 H,  $J_{OH,4}$  4.5 Hz, OH); <sup>13</sup>C-NMR (75 MHz):  $\delta_C$  (CDCl<sub>3</sub>): 166.4, 165.8, 165.3, 161.3, 143.0, 133.7, 133.5, 129.9, 129.7, 129.7, 129.3, 129.0, 128.6, 128.6, 128.5, 128.5, 125.6, 116.8, 98.8, 73.9, 73.2, 69.0, 67.1, 63.0; ESI-MS:  $m/z$  = 636.5 [M + Na]<sup>+</sup> (expected for C<sub>33</sub>H<sub>27</sub>NO<sub>11</sub>Na<sup>+</sup>:  $m/z$  = 636.2).

*p*-Nitrophenyl 4-*S*-acetyl-2,3,6-tri-*O*-benzoyl-4-deoxy-4-thio- $\beta$ -D-glucopyranoside (2):

Trifluoromethanesulfonic anhydride (0.44 ml, 0.75 g, 2.7 mmol) was added dropwise to a solution of 1 (813 mg, 1.33 mmol) in 20 ml CH<sub>2</sub>Cl<sub>2</sub> and 1.2 ml pyridine at 0°C. After 1 h at 0°C, CH<sub>2</sub>Cl<sub>2</sub> (50 ml) was added, and the organic layer was washed with saturated aqueous NaHCO<sub>3</sub>, 1M HCl and brine, dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo to give 990 mg of a yellowish solid (100%). Potassium thioacetate

(460 mg, 4.0 mmol) and HMPA (10 ml) were added, and the suspension was stirred at RT for 1 h. A mixture of EtOAc/Et<sub>2</sub>O (1:1, 50 ml) was added, and the organic layer was washed twice with water, with brine, dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo. Column chromatography (19:1 → 3:1 PE/EtOAc) and crystallization from hot EtOAc yielded **2** as a white powder (520 mg, 59%); mp 249°C (degradation); <sup>1</sup>H-NMR (300 MHz): δ<sub>H</sub> (CDCl<sub>3</sub>): 8.06 (m, 2 H, Ar), 8.02 - 7.31 (m, 15 H, 3xBz), 7.02 (m, 2 H, Ar), 5.84 (dd, 1 H, J<sub>3,4</sub> 10.8 Hz, J<sub>3,2</sub> 9.3 Hz, H-3), 5.73 (dd, 1 H, J<sub>2,3</sub> 9.3 Hz, J<sub>2,1</sub> 7.6 Hz, H-2), 5.43 (d, 1 H, J<sub>1,2</sub> 7.6 Hz, H-1), 4.79 (dd, 1 H, J<sub>6,6</sub> 12.0 Hz, J<sub>6,5</sub> 2.2 Hz, H-6), 4.54 (dd, 1 H, J<sub>6,6</sub> 12.0 Hz, J<sub>6,5</sub> 7.2 Hz, H-6), 4.37 (m, 1 H, H-5), 4.10 (t, 1 H, J<sub>4,5</sub>=J<sub>4,3</sub> 10.8 Hz, H-4), 2.28 (s, 3 H, Ac); <sup>13</sup>C-NMR (75 MHz): δ<sub>C</sub> (CDCl<sub>3</sub>): 192.7, 165.9, 165.6, 165.0, 161.1, 143.1, 138.8, 133.6, 133.6, 129.9, 129.8, 129.7, 129.4, 128.8, 128.6, 128.5, 128.4, 125.6, 116.8, 98.3, 73.7, 72.5, 71.2, 63.7, 44.3, 30.8; ESI-MS: *m/z* = 694.0 [M + Na]<sup>+</sup> (expected for C<sub>35</sub>H<sub>29</sub>NO<sub>11</sub>SNa<sup>+</sup>: *m/z* = 694.1).

*p*-Nitrophenyl 4-deoxy-4-thio-β-D-glucopyranoside (**3**):

A solution of **2** (230 mg, 0.34 mmol) in 10 ml MeOH containing catalytic amounts of MeONa was stirred for 3 h at RT. The mixture was neutralized with Amberlite IR-120PLUS (H<sup>+</sup>-form). After filtration, DTT (280 mg, 1.8 mmol) in 2 ml of degassed water was added, and N<sub>2</sub> was bubbled through the solution for 5 min. After stirring under N<sub>2</sub> overnight the mixture was concentrated in vacuo. Column chromatography (3:2 toluene/EtOAc → EtOAc) afforded **3** as a white powder (80 mg, 0.25 mmol, 74%); <sup>1</sup>H-NMR (400 MHz): δ<sub>H</sub> (d<sub>4</sub>-MeOH): 8.22 (m, 2 H, Ar), 7.23 (m, 2 H, Ar), 5.10 (d, 1 H, J<sub>1,2</sub> 7.6 Hz, H-1), 3.94 (dd, 1 H, J<sub>6,6</sub> 12.3 Hz, J<sub>6,5</sub> 1.9 Hz, H-6), 3.84 (dd, 1 H, J<sub>6,6</sub> 12.3 Hz, J<sub>6,5</sub> 4.8 Hz, H-6), 3.62 (m, 1 H, H-5), 3.49 (dd, 1 H, J<sub>2,3</sub> 9 Hz, J<sub>2,1</sub> 7.6, H-2), 3.41 (dd, 1 H, J<sub>3,4</sub> 10.2 Hz, J<sub>3,2</sub> 9.0 Hz, H-3), 2.84 (t, 1 H, J<sub>4,5</sub>=J<sub>4,3</sub> 10.2 Hz, H-4); <sup>13</sup>C-NMR (75 MHz): δ<sub>C</sub> (d<sub>4</sub>-MeOH): 163.9, 143.9, 126.6, 117.7, 101.5, 79.8, 78.8, 75.7, 62.9, 43.0; ESI-MS: *m/z* = 340.0 [M + Na]<sup>+</sup> (expected for C<sub>12</sub>H<sub>15</sub>NO<sub>7</sub>SNa<sup>+</sup>: *m/z* = 340.1).

*p*-Nitrophenyl 2,3-di-*O*-benzoyl- $\alpha$ -*L*-arabinopyranoside (4):

Benzoyl chloride (1.0 ml, 1.25 g, 8.7 mmol) was added dropwise to a solution of *p*-nitrophenyl  $\alpha$ -*L*-arabinopyranoside (1.00 g, 3.8 mmol) in DMF (30 ml) and pyridine (10 ml) at -20°C. The mixture was allowed to warm to RT overnight while stirring and worked up as compound 1. Column chromatography (5:1  $\rightarrow$  2:1 PE/EtOAc) and crystallization from EtOAc/heptane yielded 4 as a white powder (520 mg, 1.11 mmol, 29%); mp 150-151°C; <sup>1</sup>H-NMR (400 MHz):  $\delta_H$  (CDCl<sub>3</sub>): 8.18 (m, 2 H, Ar), 8.13-7.40 (m, 10 H, 2xBz), 7.08 (m, 2 H, Ar), 5.80 (dd, 1 H,  $J_{2,3}$  6.4 Hz,  $J_{2,1}$  4.2 Hz, H-2), 5.55 (dd, 1 H,  $J_{3,2}$  6.4 Hz,  $J_{3,4}$  3.3 Hz, H-3), 5.52 (d, 1 H,  $J_{1,2}$  4.2 Hz, H-1), 4.46 (m, 1 H, H-4), 4.17 (dd, 1 H,  $J_{5,5}$  11.9 Hz,  $J_{5,4}$  7.0 Hz, H-5), 3.90 (dd, 1 H,  $J_{5,5}$  11.9 Hz,  $J_{5,4}$  3.4 Hz, H-5), 2.40 (d, 1 H,  $J_{OH,4}$  5.3 Hz, OH); <sup>13</sup>C-NMR (100 MHz):  $\delta_C$  (CDCl<sub>3</sub>): 165.9, 165.0, 161.2, 142.9, 133.8, 133.7, 129.9, 129.8, 128.8, 128.6, 128.6, 125.8, 116.5, 96.8, 71.4, 69.0, 65.1, 62.9; ESI-MS:  $m/z$  = 502.0 [M + Na]<sup>+</sup> (expected for C<sub>25</sub>H<sub>21</sub>NO<sub>9</sub>Na<sup>+</sup>:  $m/z$  = 502.1).

*p*-Nitrophenyl 4-*S*-acetyl-2,3-di-*O*-benzoyl-4-deoxy-4-thio- $\beta$ -*D*-xylopyranoside (5):

The partially protected glycoside 4 (340 mg, 0.71 mmol) was treated as described for the preparation of 2. Column chromatography (6:1  $\rightarrow$  2:1 PE/EtOAc) gave xyloside 5 as a white foam (215 mg, 0.4 mmol, 56%); <sup>1</sup>H-NMR (400 MHz):  $\delta_H$  (CDCl<sub>3</sub>): 8.19 (m, 2 H, Ar), 8.1-7.35 (m, 10 H, 2xBz), 7.09 (m, 2 H, Ar), 5.60 (m, 1 H, H-3), 5.57 (m, 1 H, H-2), 5.50 (d, 1 H,  $J_{1,2}$  4.9 Hz, H-1), 4.42 (dd, 1 H,  $J_{5,5}$  12.2 Hz,  $J_{5,4}$  4.2 Hz, H-5), 4.07 (m, 1 H, H-4), 3.75 (dd, 1 H,  $J_{5,5}$  12.2 Hz,  $J_{5,4}$  7.5 Hz, H-5), 2.35 (s, 3 H, Ac); <sup>13</sup>C-NMR (100 MHz):  $\delta_C$  (CDCl<sub>3</sub>): 193.4, 165.2, 165.0, 161.1, 143.0, 133.6, 129.9, 128.9, 128.8, 128.5, 125.8, 116.6, 97.7, 70.2, 69.8, 63.4, 41.3, 30.7; ESI-MS:  $m/z$  = 560.0 [M + Na]<sup>+</sup> (expected for C<sub>27</sub>H<sub>23</sub>NO<sub>9</sub>SN<sup>+</sup>:  $m/z$  = 560.1).

*p*-Nitrophenyl 4-deoxy-4-thio- $\beta$ -*D*-xylopyranoside (6):

The protected 4-deoxy-4-thioxyloside 5 (190 mg, 0.35 mmol) was deprotected as described for compound 3. Column chromatography (1:1  $\rightarrow$  1:3 PE/EtOAc) gave 6 as a white powder (70 mg, 0.24 mmol, 69%); <sup>1</sup>H-NMR (400 MHz):  $\delta_H$  (d<sub>4</sub>-MeOH): 8.20 (m, 2 H, Ar), 7.18 (m, 2 H, Ar), 5.03 (d, 1 H,  $J_{1,2}$  7.6 Hz, H-1), 3.98 (dd, 1 H,  $J_{5,5}$  11.8 Hz,  $J_{5,4}$

5.0 Hz, H-5), 3.52 (t, 1 H,  $J_{5,5'}=J_{5,4}$  11.8 Hz, H-5), 3.44 (dd, 1 H,  $J_{2,3}$  8.9 Hz,  $J_{2,1}$  7.6 Hz, H-2), 3.32 (m, 1 H, H-3), 2.84 (m, 1 H, H-4);  $^{13}\text{C}$ -NMR (100 MHz):  $\delta_{\text{C}}$  (d<sub>4</sub>-MeOH): 163.7, 143.9, 126.6, 117.6, 102.3, 78.6, 75.9, 69.2, 42.0; ESI-MS:  $m/z$  = 310.0 [ $\text{M} + \text{Na}$ ]<sup>+</sup> (expected for  $\text{C}_{11}\text{H}_{13}\text{NO}_6\text{SNa}^+$ :  $m/z$  = 310.0).

#### Enzymatic synthesis of thiooligosaccharides:

The deoxythio sugars **3** or **6** (20 mM), the DNP-donors 2,4-dinitrophenyl  $\beta$ -D-glucopyranoside (DNP-Glc) or 2,5-dinitrophenyl  $\beta$ -D-mannopyranoside (DNP-Man) (30 mM) and the mutant enzymes Abg E171A or Man2A E429A (~1 mg ml<sup>-1</sup>) were incubated for ~3 h at RT in phosphate buffer (80 mM). DNP-Glc or DNP-Man was added to a total concentration of 45 mM, and the solution was incubated at RT for ~1 h. After lyophilization standard per-*O*-acetylation with pyridine/Ac<sub>2</sub>O and subsequent workup was performed. The final purification by column chromatography (9:1 → 1:1 toluene/EtOAc) yielded products **7-10**.

#### *p*-Nitrophenyl (2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-glucopyranosyl)-(1→4)-*S*-2,3,6-tri-*O*-acetyl-4-deoxy-4-thio- $\beta$ -D-glucopyranoside (**7**):

25 mg (64%); mp 161.5-162°C (hot toluene);  $^1\text{H}$ -NMR (400 MHz):  $\delta_{\text{H}}$  (CDCl<sub>3</sub>): 8.19 (m, 2 H, Ar), 7.09 (m, 2 H, Ar), 5.29 - 5.16 (m, 4 H, H-1, H-2, H-3', H-3), 5.06 (t, 1 H,  $J_{4,3'}=J_{4,5'}$  9.8 Hz, H-4'), 4.94 (t, 1 H,  $J_{2,1'}=J_{2,3'}$  9.6 Hz, H-2'), 4.77 (d, 1 H,  $J_{1',2'}$  10 Hz, H-1'), 4.64 (dd, 1 H,  $J_{6,6'}$  12.1 Hz,  $J_{6,5}$  1.7 Hz, H-6), 4.38 (dd, 1 H,  $J_{6,6'}$  12.1 Hz,  $J_{6,5}$  5.5 Hz, H-6), 4.31 (dd, 1 H,  $J_{6,6'}$  12.4 Hz,  $J_{6,5'}$  2.2 Hz, H-6'), 4.13 (dd, 1 H,  $J_{6,6'}$  12.4 Hz,  $J_{6,5'}$  4.8 Hz, H-6'), 4.06 (m, 1 H, H-5), 3.75 (m, 1 H, H-5'), 3.05 (t, 1 H,  $J_{4,5}=J_{4,3}$  10.6 Hz, H-4), 2.10, 2.09, 2.07, 2.06, 2.04, 2.02, 2.00 (7xs, 21 H, 7xAc);  $^{13}\text{C}$ -NMR (100 MHz):  $\delta_{\text{C}}$  (CDCl<sub>3</sub>): 170.4, 170.1, 170.0, 170.0, 169.3, 169.3, 169.2, 161.3, 143.2, 125.7, 116.7, 98.0, 81.7, 75.9, 74.6, 73.6, 72.4, 70.3, 69.9, 68.1, 63.3, 61.9, 45.8, 20.7-20.4 (7x); ESI-MS:  $m/z$  = 796.0 [ $\text{M} + \text{Na}$ ]<sup>+</sup> (expected for  $\text{C}_{32}\text{H}_{39}\text{NO}_{19}\text{SNa}^+$ :  $m/z$  = 796.2).



*p*-Nitrophenyl (2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-*S*-2,3-di-*O*-acetyl-4-deoxy-4-thio- $\beta$ -D-xylopyranoside (8):

29 mg (79%); mp 122-123°C (EtOAc/heptane);  $^1\text{H-NMR}$  (400 MHz):  $\delta_{\text{H}}$  ( $\text{CDCl}_3$ ): 8.20 (m, 2 H, Ar), 7.07 (m, 1 H, Ar), 5.21 - 5.11 (m, 4 H, H-1, H-2, H-3, H-3'), 5.07 (t, 1 H,  $J_{4,3}=J_{4,5}$  9.9 Hz, H-4'), 5.00 (dd, 1 H,  $J_{2,1}$  10 Hz,  $J_{2,3}$  9.3 Hz, H-2'), 4.63 (d, 1 H,  $J_{1,2}$  10 Hz, H-1'), 4.29 (dd, 1 H,  $J_{5,5}$  12.4 Hz,  $J_{5,4}$  4.5 Hz, H-5), 4.19 (d, 2 H,  $J_{6,5}$  3.5 Hz, 2xH-6'), 3.74 (dt, 1 H,  $J_{5,4}$  9.9 Hz and  $J_{5,6}$  3.5 Hz, H-5'), 3.65 (dd, 1 H,  $J_{5,5}$  12.4 Hz,  $J_{5,4}$  9.6 Hz, H-5), 3.23 (m, 1 H, H-4), 2.10, 2.06, 2.05, 2.03, 2.02, 2.00 (6xs, 18 H, 6xAc);  $^{13}\text{C-NMR}$  (100 MHz):  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ): 170.4, 170.0, 169.9, 169.2, 169.2, 169.0, 161.1, 143.0, 125.7, 116.5, 98.1, 81.9, 76.0 (x2), 73.6, 71.3, 69.9, 67.9, 65.6, 61.8, 42.7, 20.5 (6x); ESI-MS:  $m/z$  = 724.5  $[\text{M} + \text{Na}]^+$  (expected for  $\text{C}_{29}\text{H}_{35}\text{NO}_{17}\text{SNa}^+$ :  $m/z$  = 724.2).

*p*-Nitrophenyl (2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-mannopyranosyl)-(1 $\rightarrow$ 4)-*S*-2,3,6-tri-*O*-acetyl-4-deoxy-4-thio- $\beta$ -D-glucopyranoside (9):

5 mg (35%);  $^1\text{H-NMR}$  (400 MHz):  $\delta_{\text{H}}$  ( $\text{CDCl}_3$ ): 8.20 (m, 2 H, Ar), 7.09 (m, 2 H, Ar), 5.36 (dd, 1 H,  $J_{2,3}$  3.5 Hz,  $J_{2,1}$  1 Hz, H-2'), 5.32 - 5.17 (m, 4 H, H-1, H-2, H-3, H-4'), 5.09 (dd, 1 H,  $J_{3,4}$  10.1 Hz,  $J_{3,2}$  3.5 Hz, H-3'), 4.98 (d, 1 H,  $J_{1,2}$  1 Hz, H-1'), 4.61 (dd, 1 H,  $J_{6,6}$  12.2 Hz,  $J_{6,5}$  2.1 Hz, H-6), 4.46 (dd, 1 H,  $J_{6,6}$  12.2 Hz,  $J_{6,5}$  5.4 Hz, H-6), 4.33 (dd, 1 H,  $J_{6,6}$  12.4 Hz,  $J_{6,5}$  2.4 Hz, H-6'), 4.15 (dd, 1 H,  $J_{6,6}$  12.4 Hz,  $J_{6,5}$  5.5 Hz, H-6'), 4.08 (m, 1 H, H-5), 3.75 (m, 1 H, H-5'), 3.07 (t, 1 H,  $J_{4,5}=J_{4,3}$  10.7 Hz, H-4), 2.20, 2.12, 2.10, 2.07, 2.06, 2.06, 1.98 (7xs, 21 H, 7xAc);  $^{13}\text{C-NMR}$  (75 MHz):  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ): 170.5, 170.3, 170.3, 170.0, 169.8, 169.6, 169.2, 161.2, 143.2, 125.7, 116.6, 98.1, 79.3, 74.3, 72.1, 71.5, 69.9, 69.7, 65.7, 45.1, 20.6 (7x); ESI-MS:  $m/z$  = 796.0  $[\text{M} + \text{Na}]^+$  (expected for  $\text{C}_{32}\text{H}_{39}\text{NO}_{19}\text{SNa}^+$ :  $m/z$  = 796.2).

*p*-Nitrophenyl (2,3,4,6-tetra-*O*-acetyl- $\beta$ -D-mannopyranosyl)-(1 $\rightarrow$ 4)-*S*-2,3-di-*O*-acetyl-4-deoxy-4-thio- $\beta$ -D-xylopyranoside (10):

25 mg (82%);  $^1\text{H-NMR}$  (400 MHz):  $\delta_{\text{H}}$  ( $\text{CDCl}_3$ ): 8.20 (m, 2 H, Ar), 7.07 (m, 2 H, Ar), 5.45 (d, 1 H,  $J_{2,3}$  3.5 Hz, H-2'), 5.26-5.12 (m, 4 H, H-1, H-2, H-3, H-4'), 5.07 (dd, 1 H,  $J_{3,4}$  10.1 Hz,  $J_{3,2}$  3.5 Hz, H-3'), 4.87 (s, 1 H, H-1'), 4.28-4.15 (m, 3 H, H-5, H-6', H-

## Provisional Patent Application

6'), 3.75 (m, 1 H, H-5'), 3.66 (dd, 1 H,  $J_{5,5}$  12.4 Hz,  $J_{5,4}$  10.0 Hz, H-5), 3.28 (m, 1 H, H-4), 2.20, 2.10, 2.08, 2.06, 2.04, 2.03, 1.97 (6xs, 18 H, 6xAc);  $^{13}\text{C}$ -NMR (75 MHz):  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ): 170.4, 170.2, 170.0, 169.9, 169.6, 169.3, 161.1, 143.1, 125.8, 116.5, 98.3, 79.8, 76.8, 71.7, 71.5, 70.9, 69.8, 65.5 (2x), 62.6, 43.0, 20.5 (6x); ESI-MS:  $m/z$  = 724.5 ( $\text{M} + \text{Na}$ )<sup>+</sup> (expected for  $\text{C}_{29}\text{H}_{35}\text{NO}_{17}\text{SNa}^+$ :  $m/z$  = 724.2).

Competition study for evaluation of relative rates:

pNP-Xyl (5.5 mM), 6 (5.5 mM), DNP-Man (3.75 mM) and Man2A E429A (~1 mg  $\text{ml}^{-1}$ ) were incubated in phosphate buffer (50 mM, pH 6.8) for 3 h at RT. After removal of an aliquot DNP-Man was added to a final concentration of 22 mM. After 5 h at RT another aliquot was taken. The aliquots were diluted 1:3 with acetonitrile and centrifuged before applying to the HPLC. HPLC analysis was performed using a Waters 600E multisolvent delivery system with acetonitrile (A)/ water (B) as mobile phase (linear gradient: 80% A  $\rightarrow$  60% A in 15 min, flow: 1  $\text{ml min}^{-1}$ ), a Waters 2486 Dual  $\lambda$  Absorbance Detector (detection at 280 nm), a TOSO HAAS Amide 80 column (4.6 x 250 mm) and Millenium 3.20 software.

## References:

The following references, all of which are incorporated herein by reference, are cited herein:

- [1] Witczak, Z.J., Boryczewski, D., Bioorg. Med. Chem. Lett. 1998, 8, 3265-3268
- [2] Blanc-Meusser, M., Vigne, L., Driguez, H., Lehmann, J., Steck, J., Urbahns, K., Carbohydr. Res. 1992, 224, 59-71
- [3] Schou, C., Rasmussen, G., Schuelein, M., Henrissat, B., Driguez, H., J. Carbohydr. Chem. 1993, 12, 743-752
- [4] Sulzenbacher, G., Driguez, H., Henrissat, B., Schuelein, M., Davies, G.J., Biochemistry 1996, 35, 15280-15287
- [5] Czjzek, M., Cicek, M., Zamboni, V., Burmeister, W.P., Bevan, D.R., Henrissat, B., Esen, A., Biochem. J. 2001, 354, 37-46

- [6] Hrmova, M., Varghese, J.N., De Gori, R., Smith, B.J., Driguez, H., Fincher, G.B., Structure 2001, 9, 1005-1016
- [7] Varrot, A., Schulein, M., Fruchard, S., Driguez, H., Davies, G.J., Acta Cryst. 2001, D 57, 1739-1742
- [8] Watson, K.A., McCleverty, C., Geremia, S., Cottaz, S., Driguez, H., Johnson, L.N., EMBO J. 1999, 18, 4619-4632
- [9] Witczak, Z.J., Curr. Med. Chem. 1999, 6, 165-178
- [10] Andrews, J.S., Pinto, B.M., Carbohydr. Res. 1995, 270, 51-62
- [11] Wang, L.X., Sakairi, N., Kuzuhara, H., J. Chem. Soc. Perkin Trans.1 1990, 1677-1682
- [12] Blanc-Muesser, M., Defaye, J., Driguez, H., Carbohydr. Res. 1978, 67, 305-328
- [13] Fort, S., Varrot, A., Schulein, M., Cottaz, S., Driguez, H., Davies, G.J., Chembiochem 2001, 2, 319-325
- [14] Witczak, Z.J., Sun, J.M., Mielguj, R., Bioorg. Med. Chem. Lett. 1995, 5, 2169-2174
- [15] review: Fahey, J.W., Zalcman, A.T., Talalay, P., Phytochemistry 2001, 56, 5-51
- [16] GrootWassink, J.W.D., Reed, D.W., Kolenovsky, A.D., Plant. Physiol. 1994, 105, 425-433
- [17] Marillia, E.F., MacPherson, J.M., Tsang, B.W.T., Van Audenhove, K., Keller, W.A., GrootWassink, J.W.D., Physiol. Plantarum 2001, 113, 176-184
- [18] Mackenzie, L.F., Wang, Q.P., Warren, R.A.J., Withers, S.G., J. Am. Chem. Soc. 1998, 120, 5583-5584
- [19] Mayer, C., Zechel, D.L., Reid, S.P., Warren, R.A.J., Withers, S.G., FEBS Lett. 2000, 466, 40-44
- [20] Nashiru, O., Zechel, D.L., Stoll, D., Mohammadzadeh, T., Warren, R.A.J., Withers, S.G., Angew. Chem Int. Edit 2001, 40, 417-420
- [21] Koshland, D.E., Biol. Rev. 1953, 28, 416-436
- [22] Wang, Q., Trimbur, D., Graham, R., Warren, R.A.J., Withers, S.G., Biochemistry 1995, 34, 14554-14562
- [23] Zechel, D.L., Reid, S.P., Nashiru, O., Mayer, C., Stoll, D., Jakeman, D.L., Warren, R.A.J., Withers, S.G., J. Am. Chem. Soc. 2001, 123, 4350-4351




Fig. 1




Fig. 2




Fig. 3

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**